Evidence Summary
- Evidence Level
- Moderate
- Mechanism
- Anti-inflammatory, Enrollment: Actual, Enrollment: Estimated, Metabolic / Mitochondrial
- Safety
- GI side effects (diarrhea, nausea) common initially. Risk of B12 deficiency long-term; lactic acidosis rare (avoid in severe renal/hepatic disease, contrast).
- Dosing
- 500–2000 mg/day (extended release often better tolerated); prevention trials used during acute infection ~14 days; treatment studies 8–12+ weeks.
Prevention signal strong; treatment data mixed/preliminary. 500-2000mg. GI effects, B12. Reasonable metabolic adjunct in overweight PASC patients.
Clinical Trials
3 trial(s) registered
| NCT ID | Title | Phase | Status |
|---|---|---|---|
| NCT04510194 | COVID-OUT: Early Outpatient Treatment for SARS-CoV-2 Infection (COVID-19) | Phase 3 | Completed |
| NCT06128967 | A Multicenter, Adaptive, Randomized, doublE-blinded, Placebo-controlled Study in Participants With Long COVID-19: The REVIVE Trial | Phase 3 | Completed |
| NCT06147050 | Effect of Metformin in Reducing Fatigue in Long COVID in Adolescents | Phase 3 | Unknown status |